Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
until further notice
SourcePediatric Neurology, 39, 3, (2008), pp. 213-7
Article / Letter to editor
Display more detailsDisplay less details
Paediatrics - OUD tm 2017
SubjectDCN 1: Perception and Action; DCN 2: Functional Neurogenomics; DCN 3: Neuroinformatics; N4i 1: Pathogenesis and modulation of inflammation; NCEBP 11: Alzheimer Centre; UMCN 3.1: Neuromuscular development and genetic disorders; UMCN 3.2: Cognitive neurosciences; UMCN 4.1: Microbial pathogenesis and host defense
We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.
This item appears in the following Collection(s)
- Academic publications 
- Electronic publications 
- Faculty of Medical Sciences 
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.